← Dashboard🔄 Claude update♻ v2 refresh
NYSE · LEU
Centrus Energy Corp.
Uranium Enrichment · Fuel Supply · Nuclear Infrastructure
Price (Nov 4, 2026)
$92.58
Market Cap ~$1.97B
64% · BUY
📅 Last updated: Nov 4, 2026
Market Cap
~$1.97B
P/E (Trailing)
—
P/E (Forward)
—
Revenue (TTM)
$55.5M
Div Yield
—
Next Earnings
Feb 10, 2027 (est.)
PennyCheck™
64% BUY
Business Overview
  • What They Do: Centrus is the only US-licensed producer of High-Assay Low-Enriched Uranium (HALEU) — the advanced fuel needed for next-generation nuclear reactors including SMRs. Also brokers SWU (separative work units) and natural uranium.
  • HALEU Monopoly: Centrus operates the only US HALEU enrichment cascade at its Paducah, KY facility under a DOE contract — an irreplaceable strategic position as the SMR buildout accelerates.
  • Revenue Mix: ~$55.5M in Q3 2026 (down 25.9% YoY); revenue is lumpy due to delivery timing of multi-year enrichment contracts. Net income was positive at $1.41 EPS despite the revenue dip.
  • Contracts: Long-term enrichment contracts with US utilities and DOE provide baseline revenue visibility. The company is pursuing a commercial HALEU expansion beyond the current 6-centrifuge demo cascade.
  • Strategic Pivot: Repositioning from pure SWU broker (Russian supply dependent) to domestic enricher — directly aligned with the US energy independence push and growing SMR ecosystem.
Investment Thesis
  • AI Power Demand: Hyperscalers (Google, Microsoft, Amazon) signing long-term nuclear PPAs creates enormous new demand for enriched uranium fuel beyond traditional utility base load.
  • HALEU = Only Option: Most advanced SMR designs require HALEU (~10–20% enriched uranium). Centrus is currently the only commercial HALEU producer in the Western Hemisphere.
  • Policy Tailwinds: The ADVANCE Act (2024), Prohibiting Russian Uranium Imports Act, and DOE HALEU contracts all structurally advantage Centrus for years.
  • Lumpiness Risk: Revenue recognition is tied to delivery schedules — quarters will swing dramatically. The Q3 miss was a timing issue, not demand erosion.
  • Scale Optionality: A full commercial HALEU cascade could generate 10x+ current revenue. Capex requirements are significant but DOE cost-sharing reduces risk.
Key Metrics
Stock Price
$92.58
Nov 4, 2026
Market Cap
~$1.97B
Small-cap
Q3 2026 Revenue
$55.5M
-25.9% YoY (timing)
Q3 2026 GAAP EPS
$1.41
vs -$0.52 consensus
Revenue Miss
-6.3%
vs $59.24M consensus
Analyst Avg Target
~$130+
Pre-Q3 consensus
Financial Character
  • Revenue Lumpiness: Deliveries under multi-year enrichment contracts don't spread evenly across quarters — a revenue miss in one quarter rarely signals weakening demand.
  • Cost Structure: DOE cost-sharing on HALEU demo cascade reduces near-term cash burn. Commercial expansion will require significant capital but could unlock enormous recurring revenue.
  • Positive Net Income: GAAP EPS of $1.41 in Q3 — the company is profitable at current scale despite being a niche player.
  • No Dividend: Growth-stage capital allocation; reinvesting in HALEU expansion and regulatory work.
  • Balance Sheet: Conservative — Centrus has historically maintained modest leverage given its critical infrastructure role.
Competitive Advantages
  • Regulatory Moat (10/10): NRC license to produce HALEU is the highest barrier in any US industry. Replicating this takes 10–15 years and billions in regulatory effort — Centrus already has it.
  • First Mover: The only operating US HALEU enrichment facility. Competitors (Urenco, Orano) are foreign and cannot serve US national security contracts.
  • DOE Relationship: Paducah cascade was built under DOE contract — this government backstop is a massive advantage over any new entrant.
  • Customer Stickiness: Utility customers sign 5–10 year enrichment contracts. Switching costs are extreme given qualification, security review, and fuel cycle planning timelines.
  • SMR Alignment: Every major US SMR developer (NuScale, TerraPower, Kairos, X-energy) needs HALEU. Centrus is the chokepoint in the entire SMR supply chain.
Risk Factors
HIGH
Commercial Expansion Capex RiskScaling from 6-centrifuge demo to full commercial HALEU cascade requires hundreds of millions in investment. DOE cost-sharing mitigates but doesn't eliminate execution risk.
HIGH
Revenue Lumpiness / TimingMulti-year contracts create large quarterly revenue swings that can mislead investors — Q3 2026 revenue was down 26% while EPS beat estimates. Market often misreads these.
MED
SMR Buildout DelaysCommercial SMR deployment keeps slipping 2–3 years further out. If advanced reactor demand is delayed, HALEU demand will also lag — Centrus revenues will stay lumpy longer.
MED
Policy Reversal RiskFederal support for domestic enrichment could be deprioritized under future administrations, though national security framing makes this less likely than other energy subsidy risks.
LOW
Valuation PremiumTrading at a significant premium to current earnings given future optionality. A delay in HALEU demand could cause multiple compression.
Upcoming Catalysts
  • HALEU Commercial Expansion Award: DOE is expected to issue commercial HALEU enrichment contracts in 2026-2027. Award to Centrus would be a major re-rating event.
  • SMR Customer Contracts: As TerraPower, X-energy, and others advance toward groundbreaking, they'll need to lock in HALEU supply. Any such announcement drives LEU significantly higher.
  • Utility SWU Contract Renewals: Multiple large utility enrichment contracts come up for renewal 2026-2028; re-signing at higher prices could improve revenue floor.
  • AI Data Center Nuclear PPAs: Every hyperscaler signing a nuclear PPA increases the addressable demand for enrichment services LEU provides.
  • Congressional Support: The ADVANCE Act implementation and ongoing DOE appropriations for domestic enrichment keep the policy runway clear.
PennyCheck™ Scorecard
Business Model Clarity
4/5
Revenue Quality
3/5
Competitive Moat
5/5
Management & Execution
4/5
Balance Sheet Health
3/5
Sector Tailwinds
5/5
Valuation vs. Potential
3/5
Catalyst Pipeline
5/5
⚠ Score check: the 8 criteria above add to 32/40 = 80% (STRONG BUY), but this page shows 64%. The dashboard uses the criteria math. This gets reconciled in the next refresh. Fix with Claude →
64%
BUY — 32/50 · Strong moat, real catalysts, revenue lumpiness is the main concern
BUY
Update Log

Dated entries added after the original analysis — earnings results, guidance changes, management moves, macro shifts, score revisions.

🔄 Add an update with ClaudeAfter earnings or news: opens Claude with this ticker pre-filled; the new entry appears here a few minutes after it finishes.
No updates yet — check back after next earnings or a material news event.